---
figid: PMC8965895__fmed-09-843127-g0002
figtitle: Treatment of Androgenetic Alopecia Using PRP to Target Dysregulated Mechanisms
  and Pathways
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC8965895
filename: fmed-09-843127-g0002.jpg
figlink: /pmc/articles/PMC8965895/figure/F2/
number: F2
caption: Biochemistry of the Wnt/β-catenin signaling pathway and its crosstalk with
  androgen. (A) Constitutive phosphorylation of β-catenin by glycogen synthase kinase
  3B (GSK-3B) and subsequent proteasomal degradation of β-catenin in the absence of
  Wnt ligand. (B) Binding of Wnt ligand to Frizzled and Low-Density Lipoprotein-Related
  Protein (LRP) and the resultant inactivation of GSK-3B and its phosphorylation of
  β-catenin, which is then translocated to the nucleus to initiate the transcription
  of target genes. (C) DHT-activated AR can recruit β-catenin as a coactivator to
  stimulate the expression of DKK1, a competitive antagonist of the Wnt/β-catenin
  signaling pathway. Crosstalk between DHT-activated AR and β-catenin thus leads to
  downregulation of β-catenin target genes.
papertitle: Treatment of Androgenetic Alopecia Using PRP to Target Dysregulated Mechanisms
  and Pathways.
reftext: Rama Abdin, et al. Front Med (Lausanne). 2022;9:843127.
year: '2022'
doi: 10.3389/fmed.2022.843127
journal_title: Frontiers in Medicine
journal_nlm_ta: Front Med (Lausanne)
publisher_name: Frontiers Media S.A.
keywords: male pattern hair loss | autologous therapy | androgenetic alopecia | hair
  follicle biology | hair growth | platelet rich plasma | hair loss treatment
automl_pathway: 0.9450678
figid_alias: PMC8965895__F2
figtype: Figure
redirect_from: /figures/PMC8965895__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8965895__fmed-09-843127-g0002.html
  '@type': Dataset
  description: Biochemistry of the Wnt/β-catenin signaling pathway and its crosstalk
    with androgen. (A) Constitutive phosphorylation of β-catenin by glycogen synthase
    kinase 3B (GSK-3B) and subsequent proteasomal degradation of β-catenin in the
    absence of Wnt ligand. (B) Binding of Wnt ligand to Frizzled and Low-Density Lipoprotein-Related
    Protein (LRP) and the resultant inactivation of GSK-3B and its phosphorylation
    of β-catenin, which is then translocated to the nucleus to initiate the transcription
    of target genes. (C) DHT-activated AR can recruit β-catenin as a coactivator to
    stimulate the expression of DKK1, a competitive antagonist of the Wnt/β-catenin
    signaling pathway. Crosstalk between DHT-activated AR and β-catenin thus leads
    to downregulation of β-catenin target genes.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - LRP6
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - GSK3A
  - GSK3B
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - CTNNB1
  - LEF1
  - TCF7
  - TCF7L1
  - TCF7L2
  - HNF4A
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - AR
  - DKK1
---
